Actinium Pharmaceuticals (NYSE:ATNM) Downgraded to “Neutral” at B. Riley

Actinium Pharmaceuticals (NYSE:ATNM) was downgraded by equities researchers at B. Riley from a “buy” rating to a “neutral” rating in a research note issued to investors on Wednesday, Briefing.com reports. They presently have a $2.00 target price on the stock, down from their previous target price of $16.00. B. Riley’s price target would indicate a potential downside of 9.50% from the stock’s current price.

ATNM has been the topic of several other research reports. StockNews.com downgraded Actinium Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Monday. HC Wainwright cut their price objective on Actinium Pharmaceuticals from $50.00 to $4.00 and set a “buy” rating on the stock in a report on Tuesday. Maxim Group cut their price objective on Actinium Pharmaceuticals from $30.00 to $5.00 and set a “buy” rating on the stock in a report on Tuesday. Stephens initiated coverage on Actinium Pharmaceuticals in a report on Tuesday, May 14th. They set an “overweight” rating and a $25.00 price objective on the stock. Finally, Cantor Fitzgerald restated an “overweight” rating and set a $21.00 price objective on shares of Actinium Pharmaceuticals in a report on Tuesday, April 30th. One research analyst has rated the stock with a sell rating, one has given a hold rating and five have given a buy rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $11.43.

Actinium Pharmaceuticals Stock Performance

Shares of ATNM traded down $0.66 during midday trading on Wednesday, hitting $2.21. 1,442,334 shares of the stock traded hands, compared to its average volume of 470,411. Actinium Pharmaceuticals has a 1-year low of $1.33 and a 1-year high of $10.24. The company has a market cap of $65.82 million, a price-to-earnings ratio of -1.30 and a beta of 0.20.

Actinium Pharmaceuticals (NYSE:ATNM) last issued its quarterly earnings results on Monday, August 5th. The company reported ($0.38) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.40) by $0.02. Analysts predict that Actinium Pharmaceuticals will post -1.57 EPS for the current year.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the stock. Sanders Morris Harris LLC bought a new position in Actinium Pharmaceuticals in the first quarter valued at about $78,000. Vanguard Group Inc. boosted its holdings in Actinium Pharmaceuticals by 6.0% in the first quarter. Vanguard Group Inc. now owns 1,446,326 shares of the company’s stock valued at $11,325,000 after acquiring an additional 82,113 shares during the last quarter. Virtu Financial LLC boosted its holdings in Actinium Pharmaceuticals by 319.2% in the first quarter. Virtu Financial LLC now owns 82,029 shares of the company’s stock valued at $642,000 after acquiring an additional 62,459 shares during the last quarter. Bank of New York Mellon Corp boosted its holdings in Actinium Pharmaceuticals by 28.3% in the second quarter. Bank of New York Mellon Corp now owns 86,401 shares of the company’s stock valued at $639,000 after acquiring an additional 19,035 shares during the last quarter. Finally, Rhumbline Advisers boosted its holdings in Actinium Pharmaceuticals by 23.4% in the second quarter. Rhumbline Advisers now owns 39,656 shares of the company’s stock valued at $293,000 after acquiring an additional 7,525 shares during the last quarter. 27.50% of the stock is currently owned by institutional investors and hedge funds.

Actinium Pharmaceuticals Company Profile

Actinium Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for bone marrow transplant (BMT) or a type of cellular therapy, and for other adoptive cell therapies. Its lead product candidate, I-131 apamistamab (Iomab-B) that is in a pivotal Phase III clinical trial for elderly relapsed or refractory acute myeloid leukemia trial for BMT conditioning; and a Phase I study with a CD19- targeted CAR T-cell therapy with memorial sloan kettering cancer center.